UNDUN LONGEVITY INNOVATIONS
Raise of up to CAD$750,000
The Offering:
Up to 3,000,000 common shares (the “Shares”)
Each Share is priced at $0.25
The Offering is available to investors who qualify as “accredited investors” under National Instrument 45-106
The Shares will be subject to a standard four month plus one day hold period
If you have an interest in participating or would like more information,
please contact Marshall Farris at 604-837-4774 or marshall@ascentafinance.com.
This Offering is available on a first-come, first-serve basis. Please express your interest in participating in this financing and we will attempt to hold a position for you. Once you have been confirmed, we will provide you with a Subscription Agreement and Ascenta’s Know Your Client documentation.
About the Company:
UnDun Longevity Innovations (“UnDun” or the “Company”) is a private technology company which has developed a digital engine for longevity that transforms data into clarity. A neutral outcome engine helping every individual MEASURE what truly works for their unique journey to vitality. UnDun exists to measure what IS, not to predict what MIGHT BE. UnDun acts as a neutral, science-rooted platform that integrates, indexes, and validates real-world longevity data to reveal meaningful, usable outcomes over time.
Click here to view an overview on the Company
Click here to view the Company’s website
Use of Proceeds:
$275K
PRODUCT & AI
Build and Launch Core Platform
$190K
COHORTS & DATA
Generate First Longitudinal Dataset
$115K
PARTNERSHIPS
Integrations & Pilot Program
$75K
UX
Simple, Premium User Experience
$50K
RESEARCH
Validation & Clinical Framing
$45K
GTM & OPS
Go-To-Market & Operations
Capital & Ownership Structure:
Roughly 90% of the company remains with founders and advisors. This round is a focused early position in a clean, founder-controlled cap table with no prior institutional dilution.
Why This Matters Now?
01
Healthcare is moving from reactive to continuous monitoring.
02
Consumers are adopting wearables at unprecedented scale.
03
Longevity is becoming measurable for the first time.
05
Explosion of intervention-driven care models. GLP-1, metabolic health, longevity protocols all requiring continuous outcome measurement.
04
Growing demand for simple, interpretable health signals.
Who is it For?
Clinics and health systems measuring intervention outcomes at scale.
Digital health platforms needing outcome-labeled longitudinal data.
Wearable ecosystems adding functional health intelligence to their stack.
Research programs requiring continuous, individual-level outcome measurement.
PLEASE NOTE THAT ASCENTA
AND/OR ITS MEMBERS MAY PARTICIPATE IN THIS OFFERING.
The Company has agreed to pay Ascenta a finders fee of 7% cash.
The statements and statistics contained herein were obtained from sources believed to be reliable, but Ascenta cannot represent that they are accurate or complete.
THIS INVESTMENT IS RISKY AND YOU COULD LOSE YOUR ENTIRE INVESTMENT AMOUNT.
Consult with your investment advisor, legal or tax professionals before investing.